{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:12:04Z","timestamp":1761419524080},"reference-count":36,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.2169\/internalmedicine.9504-22","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T22:09:33Z","timestamp":1656972573000},"page":"327-334","source":"Crossref","is-referenced-by-count":2,"title":["A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer"],"prefix":"10.2169","volume":"62","author":[{"given":"Naohiro","family":"Okano","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Toki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Gondo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekatsu","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kyorin University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Kogure","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Tokyo Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Shibahara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kyorin University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.","DOI":"10.3322\/caac.21654"},{"key":"2","unstructured":"2. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2.2021 [Internet]. [cited 2021 Dec 16]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 68: 130-139, 2019.","DOI":"10.1136\/gutjnl-2017-314828"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007.","DOI":"10.1001\/jama.297.3.267"},{"key":"5","unstructured":"5. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389: 1011-1024, 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379: 2395-2406, 2018.","DOI":"10.1056\/NEJMoa1809775"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388: 248-257, 2016.","DOI":"10.1016\/S0140-6736(16)30583-9"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18: 2-11, 2018.","DOI":"10.1016\/j.pan.2017.11.011"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 207: 510-519, 2008.","DOI":"10.1016\/j.jamcollsurg.2008.04.033"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg 268: 215-222, 2018.","DOI":"10.1097\/SLA.0000000000002705"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol 26: 1629-1636, 2019.","DOI":"10.1245\/s10434-018-07131-8"},{"key":"12","unstructured":"12. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial. J Clin Oncol 38: 1763-1773, 2020."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ghaheh P, Palmer DH, Cicconi S, et al. Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol 38: 4505, 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.4505"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703, 2013.","DOI":"10.1056\/NEJMoa1304369"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.","DOI":"10.1056\/NEJMoa1011923"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ueno H, Ikeda M, Ueno M, et al. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77: 595-603, 2016.","DOI":"10.1007\/s00280-016-2972-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer. Cancer Sci 105: 1321-1326, 2014.","DOI":"10.1111\/cas.12501"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ozaka M, Ishii H, Sato T, et al. A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81: 1017-1023, 2018.","DOI":"10.1007\/s00280-018-3577-9"},{"key":"19","unstructured":"19. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2 [Internet]. 2015 [cited 2016 Feb 26]. Available from: https:\/\/www2.tri-kobe.org\/nccn\/guideline\/archive\/pancreas2015\/english\/pancreatic.pdf"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213, 2004.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127: 1335-1339, 1992.","DOI":"10.1001\/archsurg.1992.01420110083017"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Honma Y, Yamada Y, Terazawa T, et al. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today 46: 1076-1082, 2016.","DOI":"10.1007\/s00595-015-1276-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Okada KI, Hirono S, Kawai M, et al. Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res 37: 853-858, 2017.","DOI":"10.21873\/anticanres.11389"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Miyasaka Y, Ohtsuka T, Kimura R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery. Ann Surg Oncol 26: 1528-1534, 2019.","DOI":"10.1245\/s10434-019-07309-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Inoue Y, Saiura A, Oba A, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci 28: 143-155, 2021.","DOI":"10.1002\/jhbp.844"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sakaguchi T, Nakamura S, Suzuki S, et al. Marginal ulceration after pylorus-preserving pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg 7: 193-197, 2000.","DOI":"10.1007\/s005340050175"},{"key":"27","unstructured":"27. Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) [Internet]. [cited 2021 Nov 20]. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol 29: 4548-4554, 2011.","DOI":"10.1200\/JCO.2011.36.5742"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109: 926-933, 2013.","DOI":"10.1038\/bjc.2013.415"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology trial A021101. JAMA Surg 151: e161137, 2016.","DOI":"10.1001\/jamasurg.2016.1137"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nagakawa Y, Hosokawa Y, Nakayama H, et al. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol 79: 951-957, 2017.","DOI":"10.1007\/s00280-017-3288-7"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 4: 963-969, 2018.","DOI":"10.1001\/jamaoncol.2018.0329"},{"key":"33","unstructured":"33. Takahashi S, Ohno I, Ikeda M, et al. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: a phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. Forthcoming"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kato H, Usui M, Isaji S, et al. Clinical features and treatment outcome of borderline resectable pancreatic head\/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20: 601-610, 2013.","DOI":"10.1007\/s00534-013-0595-1"},{"key":"35","unstructured":"35. Pietrasz D, Sereni E, Lancelott F, et al. Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma. Br J Cancer. Forthcoming"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Takahashi H, Akita H, Ioka T, et al. Phase I trial evaluating the safety of preoperative gemcitabine\/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas 47: 1135-1141, 2018.","DOI":"10.1097\/MPA.0000000000001140"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/3\/62_9504-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T03:29:38Z","timestamp":1675481378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/3\/62_9504-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9504-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"article-number":"9504-22"}}